Sanitary Paper Product Manufacturing (U.S.) — NAICS 322291

1. Overview

This is the industry that makes the everyday paper-and-fluff hygiene products almost every household and business buys without thinking: toilet paper, paper towels, facial tissue, table napkins, and — importantly — disposable diapers, tampons, and sanitary pads. In the government's classification system, all of these fall under NAICS (North American Industry Classification System) code 322291, "Sanitary Paper Product Manufacturing." [4]

Why an investor should care: demand here is about as steady and recession-resistant as demand gets. People do not stop using toilet paper or diapers when the economy turns. That makes it a classic "consumer staple" — low growth, but durable cash flow, pricing that can be pushed through in inflation, and (for the public players) reliable dividends. The trade-off is that it is a mature, slow-growing, capital-heavy manufacturing business fought over by a handful of giants, where a few cents of wood-pulp cost per roll can swing profits.

The catch for stock-pickers is that there is no pure-play U.S.-listed sanitary-paper company of scale. The two biggest domestic public exposures — Procter & Gamble and Kimberly-Clark — are diversified household-products giants where this business is one segment among several. [8][9] The single largest U.S. tissue maker, Georgia-Pacific, is privately held inside Koch. [21] So public investors get exposure through diversified staples stocks or foreign listings; private investors reach the pure operators (private-label converters, away-from-home suppliers) through direct or private-equity ownership.

2. What it is and how it's structured

Scope. NAICS 322291 covers establishments that primarily convert purchased sanitary paper stock or wadding (raw tissue paper and absorbent "fluff") into finished sanitary products — facial tissue and handkerchiefs, table napkins, toilet paper, paper towels, disposable diapers, sanitary napkins, and tampons. [4] In practice the product mix splits into three families: at-home tissue (bath tissue, towels, facial), personal/absorbent hygiene (diapers, feminine care, adult incontinence), and away-from-home (AfH) paper for offices, hotels, restaurants, and hospitals.

The converting operation. A tissue converter buys parent rolls and embosses, laminates, perforates, rewinds, cuts, folds, packages, and palletizes them. [22] Diapers, menstrual pads, and incontinence products use a different high-speed assembly process: they combine fluff pulp with petroleum-derived films, nonwoven fabrics, adhesives, elastics, and superabsorbent material before cutting, folding, and packaging. Kimberly-Clark identifies fluff pulp as a key absorbent input and petroleum-derived materials as important components of diapers, feminine pads, wipes, and incontinence products. [9]

What it excludes (adjacent codes). The classification separates the converting step from the papermaking step:

• 322121 – Paper (except Newsprint) Mills and 322130 – Paperboard Mills make the parent rolls of paper the converters use.
• 322220 – Paper Bag and Coated/Treated Paper and 322299 – All Other Converted Paper Product capture other converted-paper goods.
• Plastic-heavy hygiene items and wet wipes can straddle other codes depending on materials.

A wrinkle to keep in mind: the biggest producers are vertically integrated — they run pulp/tissue mills and converting lines under one roof. Census assigns each plant to a single NAICS code by its primary activity, so some integrated tissue tonnage is captured upstream in the mill codes (322121) rather than in 322291. The federal 322291 figures below are best read as the converting industry, not the entire tissue-and-hygiene value chain. [4]

Capacity constraints are format-specific. Product formats are not freely interchangeable: commercial jumbo-roll equipment, consumer bath-tissue lines, folded-towel machines, and napkin lines cannot necessarily be switched when demand moves between channels. The pandemic's at-home/away-from-home mismatch demonstrated this constraint. [23]

Ownership mix. This is a concentrated, corporate manufacturing industry — not one dominated by government or by tiny sole proprietors. The top tier is a mix of U.S. public companies (Procter & Gamble, Kimberly-Clark), a large privately held domestic maker (Georgia-Pacific, owned by Koch), private-label and away-from-home specialists (Sofidel of Italy, First Quality, Cascades of Canada, Essity of Sweden), and a tail of small regional converters. [13][21]

3. How big it is

Federal statistics for NAICS 322291 (our ground-truth figures):

A few things jump out. With only about 100 firms and 138 plants producing $14.1 billion of output, this is capital-intensive and productive per worker — roughly $726,000 of shipments per employee, and an average of ~140 workers per plant. [1][2] It is also top-heavy but not a pure monopoly: the four largest firms make just under half of all shipments and the top eight make over 60%, yet it still takes 50 firms to reach 97% — so a real competitive tail of mid-size and regional converters exists beneath the giants. [1] (The Herfindahl-Hirschman Index, the standard single-number concentration measure, is suppressed in the federal data for this industry, so we do not state one.)

Undercount / definition caveats. Unlike industries dominated by government or by informal micro-operators, 322291 is not materially undercounted by the business statistics. The gaps are different: (1) the federal number is factory-gate shipment value, not retail sales — the ~$15–18 billion "market size" figures in commercial research reports typically measure toilet paper alone at retail/consumer value and use different boundaries, so they are not comparable to the $14.1 billion converting-industry number. [5][6] (2) Vertically integrated tissue tonnage can land in the mill codes rather than here (see Section 2). (3) Imports are not captured in domestic shipments — though tissue is bulky and cheap to ship, so trade is comparatively local. The most commonly misreported point is that NAICS 322291 is neither the U.S. toilet-paper market nor the complete U.S. tissue industry — it is an establishment classification covering both paper tissue and absorbent hygiene conversion, while excluding some integrated production.

4. The investable universe

There is no large U.S.-listed pure-play. The table shows where the money and the tonnage actually sit.

Bottom line for public-market investors: the cleanest large-cap ways in are PG and KMB, both broad staples names where sanitary paper is a slice, not the whole story; foreign-listed Cascades, KP Tissue, and Essity are purer but off-exchange for U.S. buyers; and the biggest single U.S. operator (Georgia-Pacific) and the fast-growing private-label players (Sofidel, First Quality) are private. [8][13][21]

5. How the money works

Owners in this industry make money on volume × price spread over input costs, run through capital-intensive plants. The specific levers:

• Staple demand, thin unit economics. Volumes barely move with the economy, so growth comes from price/mix, not from selling many more rolls. Margins live or die on the gap between selling price and the cost of wood pulp, recycled fiber, fluff pulp, petroleum-derived materials, energy, water, and freight. Northern bleached softwood kraft ("NBSK") pulp is the key swing cost; when pulp spikes, converter margins compress unless price increases stick. Kimberly-Clark states that pulp prices have historically been volatile and can materially affect results. [9][19]
• Two channels, different economics. At-home retail tissue is higher-margin and brand-driven; away-from-home (AfH) — the paper in office restrooms, hotels, and restaurants — is lower-margin, volume-oriented, and tied to foot traffic. AfH collapsed during COVID lockdowns and has only partly recovered as offices stay hybrid. [19]
• Brand premium vs. private label. Leading brands (Charmin, Bounty, Kleenex, Huggies) command premium shelf pricing and heavy advertising support; store brands ("private label") compete on price and have taken share — mid-size producers' share of the tissue market rose from 27% in 2007 to 33%. [20]
• Pricing power and "shrinkflation." Through the 2021–2023 inflation, the majors pushed multiple list-price increases and reduced sheet counts per roll; volumes softened as some shoppers traded down to private label. That episode is the clearest recent demonstration of how pricing, not volume, drives the top line. [8][19]
• Freight and scale economics. Finished tissue is bulky and low-value-per-truck, so it ships poorly — production sits near demand in regional plants, and scale in integrated mills is the main cost advantage. This is why the industry is both concentrated and regional. [19]
• Vertical integration is a mixed advantage. Owning pulp or tissue machines secures fiber and parent-roll supply and captures upstream margin, but adds commodity exposure, environmental obligations, maintenance outages, and heavy fixed costs. A converter buying parent rolls has less capital tied up but is more exposed to supplier availability and spot pricing. Utilization is critical in both models because depreciation, maintenance, and staffing continue when volumes weaken.
• What investors watch. For the public staples names: organic sales growth (price + volume/mix), gross and operating margin, free cash flow, and dividends — PG and KMB are long-standing dividend payers. FY2025 illustrates the model: P&G's overall net sales were flat at $84.3B with organic sales up 2% (a point of price, a point of volume) and $17.8B of operating cash flow. [8]

6. What drives demand

• Population and household formation set the steady baseline for tissue and towels. [4]
• Births drive diapers — and the falling U.S. birth rate is a structural headwind for diaper volume, which the majors offset with premium products and by leaning into adult categories. [8]
• Aging population drives adult incontinence (Depend, Poise, TENA) — a genuine growth pocket as the population gets older. [7]
• Menstruating population supports feminine care (tampons, pads) — a mature category facing a slow niche shift toward organic, reusable, and cup alternatives. [15]
• Away-from-home activity — office occupancy, travel, dining, events — drives AfH tissue; hybrid work is an ongoing drag on that channel. [19]
• Trade-down behavior. In downturns, shoppers shift from branded to private label and cut discretionary paper towels first — a mix headwind for the brand owners. [19]
• Hygiene shocks and pantry-loading. The 2020 toilet-paper shortage showed how a demand spike plus just-in-time supply can empty shelves; awareness elevated then normalized. [19]
• Premiumization and sustainability preference — ultra-soft, "flushable," recycled-content, and bamboo products — is reshaping the premium end of the shelf. [17]
• Substitution is real but product-specific. Bidets can reduce bath-tissue use; air dryers compete with commercial hand towels; reusable menstrual products and period underwear compete with pads and tampons; cloth diapers compete with disposables. These alternatives are more likely to limit per-capita growth than eliminate demand.

7. Regulation

Regulation is uneven across the product families:

• Feminine care is medical-device territory. Tampons and menstrual pads are regulated by the U.S. Food and Drug Administration (FDA) as medical devices, with premarket clearance (the "510(k)" pathway), manufacturing and labeling requirements, malfunction-reporting, and mandatory Toxic Shock Syndrome (TSS) warning labeling. [15] In October 2025 the FDA issued draft guidance on menstrual-product performance testing and labeling, addressing contaminants and ingredient transparency, after 2024 studies detected metals in tampons. [15][16]
• Chemical / PFAS scrutiny. There is no federal limit for PFAS ("forever chemicals") in menstrual products yet, but the FDA has been preparing a safety assessment, and states have moved first: Vermont banned intentionally added PFAS in menstrual products (2024 law, effective Jan 2026) and California restricts PFAS as well. [16] This is a reformulation and litigation risk to watch.
• Toilet paper, towels, facial tissue, and diapers are ordinary consumer products — not FDA devices — regulated for general product safety rather than medical clearance.
• "Flushable" wipes face labeling disputes and sewer-clog litigation; several states mandate "Do Not Flush" labeling on non-flushable wipes.
• Pulp and paper environmental rules. Integrated producers with pulp/tissue mills are subject to wastewater limits under EPA's 40 CFR Part 430 effluent guidelines and to hazardous-air-pollutant standards under the Pulp and Paper MACT rules. Stand-alone dry converters carry less environmental exposure. [28][29]
• Forestry and environmental pressure. Forest-certification expectations (e.g., FSC — Forest Stewardship Council), the Lacey Act on illegal logging, and FTC "Green Guides" on eco-claims all apply. [17][30] Advocacy groups have made virgin-fiber sourcing a reputational front (Section 8).

8. Competitive dynamics and consolidation

At the branded top, this is an oligopoly — Procter & Gamble, Kimberly-Clark, and Georgia-Pacific dominate at-home shelves, collectively holding roughly 60% of North American tissue capacity. [8][20][21] Beneath them, a growing mid-tier of private-label and away-from-home specialists (Sofidel, First Quality, Cascades, Essity) has been winning share as retailers push their own store brands; mid-size producers' capacity share rose from 27% in 2007 to 33%, led by investment from First Quality, Kruger, Sofidel, and Irving. [20]

Two 2024–2025 moves reshaped the field:

• Sofidel bought Clearwater Paper's private-label tissue business for ~$1.06 billion (Nov 2024), adding four U.S. plants, approximately 1,700 employees, and 340,000 metric tons of annual capacity — vaulting to #4 in North America and pulling one U.S. public company (Clearwater) out of tissue entirely. [13][14]
• Kimberly-Clark agreed to acquire Kenvue (Tylenol, Band-Aid, Neutrogena) for ~$48.7 billion (announced Nov 2025), a pivot toward higher-growth consumer health. Read as a signal: the #2 tissue-and-hygiene player is diversifying away from a mature core rather than doubling down on paper. [11][12]

The industry has also been investing heavily in new capacity (billions committed since 2024) and in decarbonizing mills — a forward-looking judgment is that capital is flowing toward private-label and AfH tonnage even as brand owners chase margin and adjacencies. [19] Barriers to entry stay high: capital intensity, freight-driven regional scale, brand equity, and retailer/slotting relationships.

Retailer concentration. Mass merchants and clubs hold significant bargaining power. Kimberly-Clark reported that Walmart represented approximately 16% of its 2025 net sales, primarily in its North America segment — company-specific evidence, but it illustrates the channel structure. [9]

Recycled fiber and sustainability. The American Forest & Paper Association reports that 90% of U.S. tissue manufacturers use some recycled paper and that tissue producers consumed approximately 3.8 million tons of recycled paper in 2024. However, recycled fibers shorten and weaken after repeated recycling, so premium softness and strength can require virgin pulp or a blend. Declining office-paper availability can also tighten the supply of high-grade recovered fiber. [31]

9. Risks

• Input-cost volatility — pulp, recycled fiber, fluff pulp, petroleum-derived materials, energy, and freight can squeeze margins fast if prices can't be passed through. [9][19]
• Private-label trade-down and retailer power — Walmart, Amazon, and Costco store brands pressure branded pricing and share. [19]
• Declining U.S. births erode diaper volume over time. [8]
• Hybrid work is a structural headwind for the away-from-home channel. [19]
• Regulatory and chemical exposure — PFAS bans and tampon-safety scrutiny raise reformulation costs and class-action risk. [16]
• Tariff and trade exposure — even locally manufactured products retain exposure to imported materials and equipment. Kimberly-Clark reported approximately $100 million of incremental tariff-related costs in 2025, primarily in North America. [9]
• Operational risks — fires, boiler or dryer failures, paper-machine outages, converting-line bottlenecks, sole-source components, electricity or gas interruptions, and labor shortages. Skilled maintenance and process labor are especially important because a small loss of machine uptime can materially reduce absorption of fixed costs. [9]
• Reputational / environmental campaigns over boreal-forest sourcing and virgin fiber; NRDC's annual "Issue with Tissue" scorecards single out the majors, and the sustainability transition carries cost. [17]
• Low organic growth — a mature category where volume is hard to grow and results lean on price, so any pricing fatigue hits directly. [8]
• Currency exposure for the globally diversified public names (PG, KMB, Essity). [8]

10. How to invest and the outlook

Public-market routes.

• Procter & Gamble (NYSE: PG) and Kimberly-Clark (NASDAQ: KMB) are the main large-cap ways in — diversified consumer-staples stocks with long dividend histories, where sanitary paper is a meaningful segment rather than the whole business. KMB's profile is changing with the pending Kenvue deal. [8][11]
• Cascades (TSX: CAS) and Essity (Nasdaq Stockholm: ESSITY-B) are purer tissue/hygiene exposures but are foreign-listed. KP Tissue (TSX: KPT) offers a narrower Canadian-listed vehicle holding ~12% of Kruger Products. [19][25][26]
• Note: Clearwater Paper (NYSE: CLW) is no longer a tissue company after its 2024 divestiture. [13] The largest single U.S. producer, Georgia-Pacific, is private (Koch). [21]
• Broad consumer-staples index funds (which hold PG and KMB) give indirect, diversified exposure without single-stock risk.

Private routes. The pure operators live here: private-label converters and away-from-home suppliers (First Quality, Sofidel, regional mills) are reached through direct ownership, private equity, or strategic acquisition — and that mid-tier is exactly where recent consolidation and capacity investment have concentrated. [13][19] Underwriting should be plant-by-plant: machine age and technology, parent-roll sourcing, customer concentration, freight radius, energy contracts, maintenance backlog, private-label contract terms, environmental liabilities, and true sustainable throughput matter more than a top-down "toilet paper market" growth estimate. The Clearwater sale at ~6× trailing adjusted EBITDA provides one private-market transaction reference. [27]

Near-term drivers to watch (forward-looking). Pulp and energy prices (the margin swing); the pace of away-from-home recovery as office attendance settles; whether private label keeps gaining share against brand pricing power; how the KMB–Kenvue integration reshapes the #2 player; PFAS/tampon reformulation timelines; tariff and trade-policy developments; and the shift toward recycled and bamboo fiber. The reasonable base case is a defensive, low-single-digit-growth industry where value is created through price/mix, cost control, and consolidation rather than category expansion — with a diaper headwind from falling births partly offset by an aging-driven incontinence tailwind. [8][16][19]

---

Sources

1. U.S. Census Bureau. "2022 Economic Census — Concentration Ratios and Statistics for the U.S. (NAICS 322291)." 2022. https://www.census.gov/programs-surveys/economic-census.html
2. U.S. Census Bureau. "2023 County Business Patterns (NAICS 322291)." 2023. https://www.census.gov/programs-surveys/cbp.html
3. U.S. Small Business Administration. "Table of Small Business Size Standards." 2023. https://www.sba.gov/document/support-table-size-standards
4. U.S. Census Bureau. "2022 NAICS Definition — 322291 Sanitary Paper Product Manufacturing." 2022. https://www.census.gov/naics/
5. Kentley Insights / MarketResearch.com. "Toilet Paper & Tissue Manufacturing — 2026 U.S. Market Research Report." 2025. https://www.marketresearch.com/Kentley-Insights-v4035/Toilet-Paper-Tissue-Manufacturing-Research-44875305/
6. Statista. "Toilet Paper — United States (Market Forecast)." 2025. https://www.statista.com/outlook/cmo/tissue-hygiene-paper/toilet-paper/united-states
7. Statista / U.S. SEC (Kimberly-Clark). "Kimberly-Clark net sales and Consumer Tissue segment, FY2024." 2025. https://www.statista.com/topics/5253/kimberly-clark/
8. Procter & Gamble Investor Relations. "P&G Announces Fourth Quarter and Fiscal Year 2025 Results" and Form 10-K FY2025. 2025. https://www.pginvestor.com/news/news-details/2025/PG-Announces-Fourth-Quarter-and-Fiscal-Year-2025-Results/default.aspx
9. U.S. Securities and Exchange Commission. "Kimberly-Clark Corp — Form 10-K, FY2025." 2025. https://www.sec.gov/Archives/edgar/data/55785/000162828026007567/kmb-20251231.htm
10. U.S. Securities and Exchange Commission. "Procter & Gamble Co — Form 10-K, FY2025." 2025. https://www.sec.gov/Archives/edgar/data/80424/000008042425000076/pg-20250630.htm
11. CNBC. "Kimberly-Clark agrees to buy Tylenol owner Kenvue in $48.7 billion deal." 2025. https://www.cnbc.com/2025/11/03/kimberly-clark-to-buy-kenvue.html
12. Kenvue Inc. Investor Relations. "Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader." 2025. https://investors.kenvue.com/financial-news/news-details/2025/Kimberly-Clark-to-Acquire-Kenvue-Creating-a-32-Billion-Global-Health-and-Wellness-Leader/default.aspx
13. Packaging Dive. "Clearwater closes $1B sale of tissue business to Sofidel." 2024. https://www.packagingdive.com/news/clearwater-sell-tissue-business-sofidel-paperboard/721956/
14. Sofidel. "Sofidel finalizes the acquisition of the Tissue division of Clearwater Paper Corporation and becomes the fourth largest tissue paper producer in North America." 2024. https://www.sofidel.com/en/press-releases/sofidel-finalizes-the-acquisition-of-the-tissue-division-of-clearwater-paper-corporation-and-becomes-the-fourth-largest-tissue-paper-producer-in-north-america/
15. U.S. Food and Drug Administration. "Menstrual Product Options, Facts, and Safe Use / Tampons." 2025. https://www.fda.gov/medical-devices/products-and-medical-procedures/menstrual-product-options-facts-and-safe-use
16. Mintz. "Congress Intensifies Tampon Safety Efforts and FDA Takes Steps to Respond." 2024. https://www.mintz.com/insights-center/viewpoints/2146/2024-09-25-congress-intensifies-tampon-safety-efforts-and-fda-takes
17. Natural Resources Defense Council (NRDC). "The Issue with Tissue." 2023–2024. https://www.nrdc.org/resources/issue-tissue
18. (Removed — consolidated into other sources.)
19. Tissue Online North America. "Competition intensifies in the U.S. tissue paper market" (private-label and mid-size share, capacity, pulp costs). 2025. https://tissueonlinenorthamerica.com/competition-intensifies-in-u-s-tissue-paper-market/
20. Tissue World Magazine. "North American Tissue Is Back on Track After the Pandemic, but Dynamic Changes Lie Ahead for the New Market." 2024. https://www.tissueworldmagazine.com/departments/exitissues/north-american-tissue-is-back-on-track-after-the-pandemic-but-dynamic-changes-lie-ahead-for-the-new-market/
21. Wikipedia / Koch, Inc. "Georgia-Pacific" (Koch subsidiary; largest North American tissue producer; brand portfolio). 2025. https://en.wikipedia.org/wiki/Georgia-Pacific
22. American Forest & Paper Association. "How Is Paper Made Today?" 2025. https://www.afandpa.org/news/2025/how-paper-made-today
23. TAPPI / Paper360. "Coronavirus to Alter Global Toilet Paper, Tissue Production." 2020. https://paper360.tappi.org/2020/10/30/coronavirus-to-alter-global-toilet-paper-tissue-production/
24. Georgia-Pacific. "Consumer Products Overview." 2025. https://www.gp.com/product-overview/consumer-products
25. Cascades Inc. "Cascades Reports Results for Fourth Quarter and Full Year 2025." 2025. https://www.cascades.com/en/news/cascades-reports-results-fourth-quarter-full-year-2025
26. KP Tissue Inc. Investor Relations — Shareholder Information. 2025. https://www.kptissueinc.com/investor-relations/shareholder-information
27. Clearwater Paper Corporation. "Clearwater Paper Enters into Definitive Agreement to Sell Tissue Business to Sofidel America Corporation for $1.06 Billion." 2024. https://www.clearwaterpaper.com/investors/press-releases/news-details/2024/Clearwater-Paper-Enters-into-Definitive-Agreement-to-Sell-Tissue-Business-to-Sofidel-America-Corporation-for-1.06-Billion/default.aspx
28. U.S. Environmental Protection Agency. "Pulp, Paper, and Paperboard Effluent Guidelines (40 CFR Part 430)." https://www.epa.gov/eg/pulp-paper-and-paperboard-effluent-guidelines
29. U.S. Environmental Protection Agency. "Pulp and Paper Production (MACT I, II, III) National Emissions Standards." https://www.epa.gov/stationary-sources-air-pollution/pulp-and-paper-production-mact-i-iii-national-emissions-standards
30. Federal Trade Commission. "Green Guides." https://www.ftc.gov/news-events/topics/truth-advertising/green-guides
31. American Forest & Paper Association. "Tissue Products." 2025. https://www.afandpa.org/paper-wood-products/tissue